QBie™ Spotlight: BioVie Inc. (OTCQB: BIVI)

QBie™ Spotlight joins Jonathan M. Adams, CEO of BioVie Inc. (OTCQB: BIVI), to discuss one of the OTCQB’s newest additions. BIVI joined the OTCQB on March 3, 2017.  

What does BioVie do?

Jonathan M. Adams (CEO – OTCQB: BIVI):  “BioVie Inc. is a clinical-stage company developing innovative drug therapies for liver disease. Our lead compound is BIV201, a novel approach to the treatment of ascites due to liver cirrhosis. In March 2017, BioVie received notification from the FDA permitting it to initiate a Phase 2 US clinical trial. BIV201, which has Orphan Drug designation and patent protection, has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The FDA has never approved any drug specifically for treating ascites.”   



What is the next big goal BIVI is trying to accomplish/what should we keep an eye out for? 


Jonathan Adams: “We expect to commence dosing our first patient with BIV201 this June. Based on ex-US studies we hope to establish safety, with signs of efficacy, in the first group of 6 refractory ascites patients. The active agent in BIV201,terlipressin, is approved for treating related conditions in about 40 countries but not the US. If this trial is successful it will be a major milestone for BioVie.” 


Why did you join the OTCQB/go public?

Jonathan Adams: “We up-listed from a PINK sheet stock to OTCQB to realize the benefits of increased recognition and quality, and to access all of the services available. This also supported stock registration to enable access to our $11.8 million equity line with Aspire Capital Fund.”  

How can members of the microcap community help you?

Jonathan Adams: “By tracking the progress of our company and evaluating BIVI stock. Our product pipeline information, recent press releases and SEC filings are available on our website biovieinc.com.

Learn more about BioVie Inc. (OTCQB: BIVI) at: www.biovieinc.com

About QBie™ Spotlight:

QBie™ Spotlight is a virtual “welcome interview” for new OTCQB companies. QBie™ Spotlight helps issuers that are new to the OTCQB connect with microcap industry professionals! Learn more about the QBie™ Spotlight HERE.

Disclaimer/Forward Looking Statements: 

This Website and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities. No investment advice is provided or should be construed to be provided herein. This Website and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker-dealers or registered investment advisors. This Website may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein. Accordingly, user of this Website are cautioned not to place undue reliance on such forward-looking statements. This Website undertakes no obligation to update any forward-looking statements that may be contained herein.




QBie™ Spotlight



OTC Markets


BioVie Inc. (OTCQB: BIVI)



Jonathan Adams

MicroCap CEOs

Leave a Reply